Clinical Trials Logo

Clinical Trial Summary

The objective of this Study is to evaluate the safety and efficacy of the IN.PACT Admiral® drug coated PTA balloon, utilized for the dilatation of the narrowed sections of the artery, as compared to other standard (non drug coated) PTA balloons. The IN.PACT Admiral, besides the mechanical dilatation effect typical of all PTA balloons, releases a drug (paclitaxel) from the balloon surface into the vessel walls. This drug absorption is intended to limit the chances and the entity of artery re-narrowing over time.


Clinical Trial Description

The efficacy of the IN.PACT Admiral balloon will be evaluated by assessing the primary patency rate of the treated arteries in the thighs of all patients included in the Study. Primary patency is a measure of the durability up to 1 year of the free lumen in the artery as restored during the procedure and is based on:

- the need for re-dilatation of the previously treated vessel segment

- an ultrasound examination The safety of the IN.PACT Admiral will be assessed by evaluating the incidence of deaths, amputations and re-dilatation of the pre-treated arteries in all patients included in the Study.

The IN.PACT SFA Trial enrolled in 2 phases: IN.PACT SFA I and IN.PACT SFA II. The 150-patient IN.PACT SFA I phase is intended to support the second phase IN.PACT SFA II IDE trial with congruent design and protocol. Aggregate data from the two phases is intended to provide statistical power for the 12-month primary safety and effectiveness endpoints. ;


Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01175850
Study type Interventional
Source Medtronic Endovascular
Contact
Status Active, not recruiting
Phase N/A
Start date September 2010
Completion date June 2016

See also
  Status Clinical Trial Phase
Active, not recruiting NCT00707876 - Magnetic Resonance Angiography for Peripheral Arterial Disease (PAD) Phase 2
Completed NCT00760565 - A Multiple Ascending Dose Study of RO4905417 in Healthy Volunteers and Patients With Peripheral Arterial Disease (PAD). Phase 1
Recruiting NCT04631848 - ULTRASCORE™ Focused Force PTA Balloon Angioplasty for CLI Patients With Below the Knee Vessel Disease
Completed NCT00196066 - Evaluation of the Zilver Vascular Stent in the Iliac Arteries (ZIPS) Phase 2
Recruiting NCT05834673 - VICTORION-ASCERTAIN: Implementation Study (v-ASCERTAIN) Phase 4
Recruiting NCT05498740 - Post-marketing Study in Femoral Popliteal Artery of Drug Coated Balloon Used for Treatment of Lower Limb Ischemia N/A
Completed NCT02780349 - Evaluation of WIRION™ EPS in Lower Extremities Arteries N/A
Completed NCT02254356 - Zilver Flex Post-Market Study in Japan N/A
Completed NCT02254837 - Zilver PTX Post-Market Study in Japan N/A
Completed NCT00689377 - Prevalence of Peripheral Arterial Disease in Subject With a Moderate Risk of Cardiovascular (CV) Disease (CVD) in Primary Prevention N/A
Active, not recruiting NCT05149664 - A Non-significant Risk Clinical Study: Changes in Perfusion After Therapeutic Ultrasound in Patients With PAD N/A
Recruiting NCT04749732 - Home-based Exercise Therapy for Patients With PAD N/A
Completed NCT02936622 - Paclitaxel-coated Peripheral Stents Used in the Treatment of Femoropopliteal Stenoses N/A
Completed NCT00862420 - Safety Evaluation of Clopidogrel Sulfate in Patients With Peripheral Arterial Disease Phase 3
Completed NCT00827619 - Zilver® Flex™ Vascular Stent Study N/A
Completed NCT04753372 - Rivaroxaban Plus Aspirin in Patients With Chronic Coronary Syndrome and High Ischemic Risk
Not yet recruiting NCT06457685 - Amplitude Vascular Systems (AVS) Lithotripsy POWER PAD 2 Trial N/A
Recruiting NCT05246410 - A Clinical Trial to Evaluate the Efficacy and Safety of a Spot Stent System Used in Femoropopliteal Arteries. N/A
Terminated NCT03111238 - The Efficacy and Safety of REX-001 to Treat Ischemic Rest Pain in Subjects With CLI Rutherford Category 4 and DM Phase 3
Terminated NCT03174522 - The Efficacy and Safety of REX-001 to Treat Ischemic Ulcers in Subjects With CLI Rutherford Category 5 and DM Phase 3